文献速递流行病学与生物统计临床试验与 GCP

部分参与者治疗偏好不确定时两阶段随机试验设计的优化

Optimising the two-stage randomised trial design when some participants are indifferent in their treatment preferences.
PubMed 文献 · Stat Med · 2019-02-22

两阶段随机试验设计允许部分患者选择治疗、其余随机分配,从而估计偏好效应。本文针对部分参与者无法或不愿表达治疗偏好的情况,提出应将其作为独立组分析以获得有效偏好效应估计,并推导了应提供治疗选择的最优参与者比例,该比例在许多情况下接近50%。最优值取决于治疗偏好率、未决定参与者比例及主要关注参数。

要点

  • 未决定治疗偏好的参与者应在分析中作为独立组处理,以获得有效的偏好效应估计。
  • 应提供治疗选择的最优参与者比例在许多情况下接近50%。
  • 最优设计取决于偏好率、未决定比例及主要关注参数。

核心结论

  • 当部分参与者对治疗偏好不确定时,两阶段随机试验设计仍可优化,未决定组应作为独立组分析以获得有效偏好效应估计。
  • 应提供治疗选择的最优参与者比例在许多情况下接近50%,但一般取决于偏好率、未决定比例及主要关注参数。

研究设计与样本

  • 两阶段随机试验设计:部分患者可选择治疗,其余随机分配。
  • 本文扩展方法学以允许分配到选择组的参与者无法或不愿表达治疗偏好,并推导最优设计参数。

主要发现

  • 未决定组应视为独立组分析,以获得有效的偏好效应估计。
  • 推导出应提供治疗选择的最优参与者比例,许多情况下接近50%。
  • 最优值取决于治疗偏好率、未决定参与者比例及主要关注参数。

关键数值与推荐

  • 应提供治疗选择的最优参与者比例在许多情况下接近50%。

临床怎么用

  • 设计两阶段随机试验时,若预期存在偏好不确定的参与者,应将其作为独立组分析并据此优化选择组比例。

局限性

  • 文中讨论了两阶段试验设计在此情况下的优缺点,并描述了一个实际例子。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Outcomes in a clinical trial can be affected by any underlying preferences that its participants have for the treatments under comparison and by whether they actually receive their preferred treatment. These effects cannot be evaluated in standard trial designs but are estimable in the alternative two-stage randomised trial design, in which some patients can choose their treatment, while the rest are randomly assigned. We have previously shown that, when all two-stage trial participants have a preferred treatment, the preference effects can be evaluated, in addition to the usual direct effect of treatment. We also determined criteria by which to optimise how many participants should be given a choice of treatment vs being randomised. More recently, we extended our methodology to allow for participants who are unable or unwilling to express a treatment preference if they are assigned to the choice group. In this paper, we show how to optimise the two-stage design when some participants are undecided about their treatment. We demonstrate that the undecided group should be regarded as distinct in the analysis, to obtain valid estimates of the preference effects. We derive the optimal proportion of participants who should be offered a choice of treatment, which in many cases will be close to 50%. More generally, the optima depend on the preference rates for treatments and the proportion of undecided participants, and the parameters of primary interest. We discuss some advantages and disadvantages of the two-stage trial design in this situation and describe a practical example.

来源:Stat Med,查看原文。版权归原作者所有。

引用

  1. Walter SD, Turner RM, Macaskill P, et al. Optimising the two-stage randomised trial design when some participants are indifferent in their treatment preferences. Stat Med. 2019. PMID: 30793786. doi:10.1002/sim.8119

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。